Ownership and insider activity for Silence Therapeutics plc (SLN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver.
Price
| Price | $12.50 |
| Market Cap | $590M |
| Exchange | NASDAQ |
| Country | GB |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39.0M | $42.7M | $21.5M | $13.5M | $27.4M | $73.5M | $54.8M | $54.4M | $96.9M | $11.3M |
| Short-term Investments | 0 | $319000 | $5.0M | $20.0M | $10.0M | 0 | $16.3M | 0 | $20.8M | $73.8M |
| Receivables | $810000 | $2.0M | $2.4M | $4000 | $29.3M | $331000 | $915000 | $19.0M | $776375 | $24.6M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $42.0M | $45.5M | $29.5M | $37.5M | $76.4M | $86.3M | $96.7M | $81.6M | $149.7M | $118.7M |
| Property, Plant & Equipment | $1.4M | $1.2M | $921000 | $611000 | $1.1M | $1.9M | $2.2M | $2.3M | $1.6M | $1.7M |
| Goodwill | $7.7M | $8.0M | $8.1M | $7.7M | $8.1M | $7.6M | $8.0M | $10.0M | $7.5M | $10.6M |
| Intangible Assets | $45000 | $28000 | $64000 | $34000 | $17000 | $24000 | $320000 | $362000 | $249206 | $288000 |
| Total Assets | $55.8M | $55.0M | $38.9M | $46.1M | $86.0M | $96.2M | $107.5M | $94.5M | $161.9M | $131.4M |
| Accounts Payable | $528000 | $462000 | $1.1M | $1.8M | $2.3M | $4.1M | $3.2M | $2.6M | $3.0M | $4.4M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.6M | $2.7M | $3.8M | $9.7M | $25.6M | $15.2M | $21.9M | $17.7M | $13.4M | $13.6M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $1.6M | $2.7M | $3.8M | $25.2M | $76.9M | $87.7M | $85.4M | $77.1M | $54.8M | $69.1M |
| Retained Earnings | -$116.0M | -$116.4M | -$133.8M | -$152.0M | -$184.2M | -$223.0M | -$263.3M | -$431.9M | -$378.6M | -$562.6M |
| Total Equity | $54.2M | $52.4M | $35.1M | $20.9M | $9.1M | $8.5M | $22.1M | $22.0M | $107.0M | $62.3M |
| Total Debt | 0 | 0 | 0 | $287000 | $341000 | $137000 | $446000 | $273808 | $93452 | $160000 |
| Net Debt | -$39.0M | -$43.1M | -$26.5M | -$33.2M | -$37.1M | -$73.4M | -$70.7M | -$54.2M | -$117.6M | -$85.0M |
| Working Capital | $40.4M | $42.9M | $25.7M | $27.8M | $50.8M | $71.2M | $74.7M | $64.0M | $136.2M | $105.0M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 7.42 |
Profitability
| Return on Equity | -106.94% |
| Return on Invested Capital | -71.25% |
| Return on Assets | -56.34% |
| Gross Margin | 51.00% |
| Operating Margin | -10880.25% |
| Net Margin | -9759.23% |
Related companies: ACIU · ALDX · AMRN · ANRO · CAPR · CTNM · KYTX
Explore sector: Healthcare · Biotechnology
More sections of SLN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks